YTHDF2-mediated m6A modification of ONECUT2 promotes stemness and oxaliplatin resistance in gastric cancer through transcriptionally activating TFPI
Drug Resistance Updates · 2025-03 · 79 · 101200
DOI: 10.1016/j.drup.2024.101200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2025-03. Verfasst von Xingdi Fan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510280, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Oxaliplatin, Drug Resistance, Neoplasm, RNA-Binding Proteins. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
AIMS: Chemoresistance results in poor outcomes of patients with gastric cancer (GC). This study aims to identify oxaliplatin resistance-related cell subpopulations in the tumor microenvironment (TME) and decipher the involved molecular mechanisms. METHODS: Through single-cell RNA sequencing, a unique ONECUT2+TFPI+ GC cell subset was identified in the oxaliplatin-resistant TME. The functional roles and molecular mechanisms of ONECUT2 in oxaliplatin resistance were investigated in cellular and mouse models. Therapeutic efficacy of small molecule inhibitor of ONECUT2 was also evaluated. RESULTS: The abundance of ONECUT2+TFPI+ GC cell subset was elevated in oxaliplatin-resistant GC tumors. ONECUT2 was up-regulated and associated with undesirable prognostic outcomes of patients with GC. ONECUT2 facilitated GC cell migration, stemness properties and oxaliplatin resistance. YTHDF2, an m6A "reader", was down-regulated in GC, and its overexpression facilitated ONECUT2 mRNA degradation through m6A modification. Furthermore, ONECUT2 transcriptionally activated TFPI through binding to its promoter. Small molecule inhibitor CSRM617 targeting ONECUT2 was well tolerated in GC mouse models, and could effectively improve therapeutic efficacy of oxaliplatin against GC. CONCLUSIONS: Our study demonstrates that YTHDF2-mediated m6A modification of ONECUT2 results in stemness and oxaliplatin resistance in GC through transcriptionally activating TFPI, which provides a novel therapeutic target against oxaliplatin-resistant GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510280, China.
- Yue Bei People's Hospital Postdoctoral Innovation Practice Base, Southern Medical University, Guangzhou, Guangdong 510515, China; Department of Pathology, Nanfang Hospital, School of Basic Medical Sciences, Southern Med…
- Department of Pathology, Nanfang Hospital, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong 510515, China.
- The First School of Clinical Medicine, Guangzhou Medical University, Guangzhou, Guangdong 511436, China.
- Experimental Center of BIOQGene, YuanDong International Academy Of Life Sciences, 999077, Hong Kong.
- Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510280, China; Experimental Center of BIOQGene, YuanDong International Academy Of Life Sciences, 999077, Hong Kong. Ele…
Förderung
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Fan, X., Han, F., Wang, H., Shu, Z., Qiu, B., Zeng, F., Chen, H., Wu, Z., Lin, Y., Lan, Z., Ye, Z., Ying, Y., Geng, T., Xian, Z., Niu, X., Wu, J., Mo, K., Zheng, K., Ye, Y., & Cui, C. (2025). YTHDF2-mediated m6A modification of ONECUT2 promotes stemness and oxaliplatin resistance in gastric cancer through transcriptionally activating TFPI. Drug Resistance Updates, 79, 101200. https://doi.org/10.1016/j.drup.2024.101200
Vancouver
Fan X, Han F, Wang H, Shu Z, Qiu B, Zeng F, et al. YTHDF2-mediated m6A modification of ONECUT2 promotes stemness and oxaliplatin resistance in gastric cancer through transcriptionally activating TFPI. Drug Resistance Updates. 2025;79:101200. doi:10.1016/j.drup.2024.101200
BibTeX
@article{Fan2025,
author = {Fan, Xingdi and Han, Fangyi and Wang, Haocheng and Shu, Zhilin and Qiu, Bowen and Zeng, Fanan and Chen, Hongzhen and Wu, Ziying and Lin, Yongwei and Lan, Zhien and Ye, Zhiwei and Ying, Yao and Geng, Tiansu and Xian, Ziqian and Niu, Xing and Wu, Junming and Mo, Ke and Zheng, Kehong and Ye, Yaping and Cui, Chunhui},
title = {YTHDF2-mediated m6A modification of ONECUT2 promotes stemness and oxaliplatin resistance in gastric cancer through transcriptionally activating TFPI},
journal = {Drug Resistance Updates},
year = {2025},
volume = {79},
pages = {101200},
doi = {10.1016/j.drup.2024.101200}
}
EUVIMED